China Pharma And Distributors Suffer From Essential Drug List System And Price Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
Morgan Stanley analysts poured cold water on investor hopes in Hong Kong by downgrading pharma and distribution sectors in a July 7 research note.
You may also be interested in...
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
SHANGHAI - Last year was a banner year for China's life sciences companies, with 34 new stock offerings globally that raised $6.9 billion from the capital market. But the first half of 2011 has been a disappointment across healthcare sectors for Chinese firms
In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model
SHANGHAI - Since China's healthcare reforms started in 2009, the central government has been encouraging local government to pilot different tender models for essential drugs to reduce public medical expenses. Anhui Province's tender system became a successful example by reducing essential drug prices an average 40-50% last year, and now the central government is implementing a single supplier procurement system, the so-called Anhui model, nationwide
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma